Browsing by Author "Antó, JM"

Now showing 1 - 4 of 4
  • No Thumbnail Available
    Item
    Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK-air(R) real-world data
    Sousa-Pinto, B; Sá-Sousa, A; Vieira, RJ; Amaral, R; Klimek, L; Czarlewski, W; Antó, JM; Pfaar, O; Bedbrook, A; Kvedariene, V; Ventura, MT; Ansotegui, IJ; Bergmann, KC; Brussino, L; Canonica, GW; Cardona, V; Carreiro-Martins, P; Casale, T; Cecchi, L; Chivato, T; Chu, DK; Cingi, C; Costa, EM; Cruz, AA; De Feo, G; Devillier, P; Fokkens, WJ; Gaga, M; Gemicioglu, B; Haahtela, T; Ivancevich, JC; Ispayeva, Z; Jutel, M; Kuna, P; Kaidashev, I; Kraxner, H; Larenas-Linnemann, DE; Laune, D; Lipworth, B; Louis, R; Makris, M; Monti, R; Morais-Almeida, M; Mösges, R; Mullol, J; Odemyr, M; Okamoto, Y; Papadopoulos, NG; Patella, V; Pham-Thi, N; Regateiro, FS; Reitsma, S; Rouadi, PW; Samolinski, B; Sova, M; Todo-Bom, A; Taborda-Barata, L; Tomazic, PV; Toppila-Salmi, S; Sastre, J; Tsiligianni, I; Valiulis, A; Vandenplas, O; Wallace, D; Waserman, S; Yorgancioglu, A; Zidarn, M; Zuberbier, T; Fonseca, JA; Bousquet, J
    Background Co-medication is common among patients with allergic rhinitis (AR), but its dimension and patterns are unknown. This is particularly relevant since AR is understood differently across European countries, as reflected by rhinitis-related search patterns in Google Trends. This study aims to assess AR co-medication and its regional patterns in Europe, using real-world data. Methods We analysed 2015-2020 MASK-air(R) European data. We compared days under no medication, monotherapy and co-medication using the visual analogue scale (VAS) levels for overall allergic symptoms ('VAS Global Symptoms') and impact of AR on work. We assessed the monthly use of different medication schemes, performing separate analyses by region (defined geographically or by Google Trends patterns). We estimated the average number of different drugs reported per patient within 1 year. Results We analysed 222,024 days (13,122 users), including 63,887 days (28.8%) under monotherapy and 38,315 (17.3%) under co-medication. The median 'VAS Global Symptoms' was 7 for no medication days, 14 for monotherapy and 21 for co-medication (p < .001). Medication use peaked during the spring, with similar patterns across different European regions (defined geographically or by Google Trends). Oral H-1-antihistamines were the most common medication in single and co-medication. Each patient reported using an annual average of 2.7 drugs, with 80% reporting two or more. Conclusions Allergic rhinitis medication patterns are similar across European regions. One third of treatment days involved co-medication. These findings suggest that patients treat themselves according to their symptoms (irrespective of how they understand AR) and that co-medication use is driven by symptom severity.
  • No Thumbnail Available
    Item
    Validity, reliability, and responsiveness of daily monitoring visual analog scales in MASK-air®
    Sousa-Pinto, B; Eklund, P; Pfaar, O; Klimek, L; Zuberbier, T; Czarlewski, W; Bédard, A; Bindslev-Jensen, C; Bedbrook, A; Bosnic-Anticevich, S; Brussino, L; Cardona, V; Cruz, AA; de Vries, G; Devillier, P; Fokkens, WJ; Fuentes-Pérez, JM; Gemicioglu, B; Haahtela, T; Huerta-Villalobos, YR; Ivancevich, JC; Kull, I; Kuna, P; Kvedariene, V; Linnemann, DEL; Laune, D; Makris, M; Melén, E; Morais-Almeida, M; Mösges, R; Mullol, J; O'Hehir, RE; Papadopoulos, NG; Pereira, AM; Prokopakis, EP; Psarros, F; Regateiro, FS; Reitsma, S; Samolinski, B; Scichilone, N; da Silva, J; Stellato, C; Todo-Bom, A; Tomazic, PV; Salmi, ST; Valero, A; Valiulis, A; Valovirta, E; van Eerd, M; Ventura, MT; Yorgancioglu, A; Basagaña, X; Antó, JM; Bousquet, J; Fonseca, JA
    Background MASK-air (R) is an app that supports allergic rhinitis patients in disease control. Users register daily allergy symptoms and their impact on activities using visual analog scales (VASs). We aimed to assess the concurrent validity, reliability, and responsiveness of these daily VASs. Methods Daily monitoring VAS data were assessed in MASK-air (R) users with allergic rhinitis. Concurrent validity was assessed by correlating daily VAS values with those of the EuroQol-5 Dimensions (EQ-5D) VAS, the Control of Allergic Rhinitis and Asthma Test (CARAT) score, and the Work Productivity and Activity Impairment Allergic Specific (WPAI-AS) Questionnaire (work and activity impairment scores). Intra-rater reliability was assessed in users providing multiple daily VASs within the same day. Test-retest reliability was tested in clinically stable users, as defined by the EQ-5D VAS, CARAT, or VAS Work (i.e., VAS assessing the impact of allergy on work). Responsiveness was determined in users with two consecutive measurements of EQ-5D-VAS or VAS Work indicating clinical change. Results A total of 17,780 MASK-air (R) users, with 317,176 VAS days, were assessed. Concurrent validity was moderate-high (Spearman correlation coefficient range: 0.437-0.716). Intra-rater reliability intraclass correlation coefficients (ICCs) ranged between 0.870 (VAS assessing global allergy symptoms) and 0.937 (VAS assessing allergy symptoms on sleep). Test-retest reliability ICCs ranged between 0.604 and 0.878-VAS Work and VAS asthma presented the highest ICCs. Moderate/large responsiveness effect sizes were observed-the sleep VAS was associated with lower responsiveness, while the global allergy symptoms VAS demonstrated higher responsiveness. Conclusion In MASK-air (R), daily monitoring VASs have high intra-rater reliability and moderate-high validity, reliability, and responsiveness, pointing to a reliable measure of symptom loads.
  • No Thumbnail Available
    Item
    Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air® App
    Bédard, A; Antó, JM; Fonseca, JA; Arnavielhe, S; Bachert, C; Bedbrook, A; Bindslev-Jensen, C; Bosnic-Anticevich, S; Cardona, V; Cruz, AA; Fokkens, WJ; Garcia-Aymerich, J; Hellings, PW; Ivancevich, JC; Klimek, L; Kuna, P; Kvedariene, V; Larenas-Linnemann, D; Melén, E; Monti, R; Mösges, R; Mullol, J; Papadopoulos, NG; Nhan, PT; Samolinski, B; Tomazic, PV; Toppila-Salmi, S; Ventura, MT; Yorgancioglu, A; Bousquet, J; Pfaar, O; Basagaña, X
    Background In allergic rhinitis, a relevant outcome providing information on the effectiveness of interventions is needed. In MASK-air (Mobile Airways Sentinel Network), a visual analogue scale (VAS) for work is used as a relevant outcome. This study aimed to assess the performance of the work VAS work by comparing VAS work with other VAS measurements and symptom-medication scores obtained concurrently. Methods All consecutive MASK-air users in 23 countries from 1 June 2016 to 31 October 2018 were included (14 189 users; 205 904 days). Geolocalized users self-assessed daily symptom control using the touchscreen functionality on their smart phone to click on VAS scores (ranging from 0 to 100) for overall symptoms (global), nose, eyes, asthma and work. Two symptom-medication scores were used: the modified EAACI CSMS score and the MASK control score for rhinitis. To assess data quality, the intra-individual response variability (IRV) index was calculated. Results A strong correlation was observed between VAS work and other VAS. The highest levels for correlation with VAS work and variance explained in VAS work were found with VAS global, followed by VAS nose, eye and asthma. In comparison with VAS global, the mCSMS and MASK control score showed a lower correlation with VAS work. Results are unlikely to be explained by a low quality of data arising from repeated VAS measures. Conclusions VAS work correlates with other outcomes (VAS global, nose, eye and asthma) but less well with a symptom-medication score. VAS work should be considered as a potentially useful AR outcome in intervention studies.
  • No Thumbnail Available
    Item
    Real-world data using mHealth apps in rhinitis, rhinosinusitis and their multimorbidities
    Sousa-Pinto, B; Anto, A; Berger, M; Dramburg, S; Pfaar, O; Klimek, L; Jutel, M; Czarlewski, W; Bedbrook, A; Valiulis, A; Agache, I; Amaral, R; Ansotegui, IJ; Bastl, K; Berger, U; Bergmann, KC; Bosnic-Anticevich, S; Braido, F; Brussino, L; Cardona, V; Casale, T; Canonica, GW; Cecchi, L; Charpin, D; Chivato, T; Chu, DK; Cingi, C; Costa, EM; Cruz, AA; Devillier, P; Durham, SR; Ebisawa, M; Fiocchi, A; Fokkens, WJ; Gemicioglu, B; Gotua, M; Guzmán, MA; Haahtela, T; Ivancevich, JC; Kuna, P; Kaidashev, I; Khaitov, M; Kvedariene, V; Larenas-Linnemann, DE; Lipworth, B; Laune, D; Matricardi, PM; Morais-Almeida, M; Mullol, J; Naclerio, R; Neffen, H; Nekam, K; Niedoszytko, M; Okamoto, Y; Papadopoulos, NG; Park, HS; Passalacqua, G; Patella, V; Pelosi, S; Nhan, PT; Popov, TA; Regateiro, FS; Reitsma, S; Rodriguez-Gonzales, M; Rosario, N; Rouadi, PW; Samolinski, B; Sá-Sousa, A; Sastre, J; Sheikh, A; Ulrik, CS; Taborda-Barata, L; Todo-Bom, A; Tomazic, PV; Toppila-Salmi, S; Tripodi, S; Tsiligianni, I; Valovirta, E; Ventura, MT; Valero, AA; Vieira, RJ; Wallace, D; Waserman, S; Williams, S; Yorgancioglu, A; Zhang, L; Zidarn, M; Zuberbier, J; Olze, H; Antó, JM; Zuberbier, T; Fonseca, JA; Bousquet, J
    Digital health is an umbrella term which encompasses eHealth and benefits from areas such as advanced computer sciences. eHealth includes mHealth apps, which offer the potential to redesign aspects of healthcare delivery. The capacity of apps to collect large amounts of longitudinal, real-time, real-world data enables the progression of biomedical knowledge. Apps for rhinitis and rhinosinusitis were searched for in the Google Play and Apple App stores, via an automatic market research tool recently developed using JavaScript. Over 1500 apps for allergic rhinitis and rhinosinusitis were identified, some dealing with multimorbidity. However, only six apps for rhinitis (AirRater, AllergyMonitor, AllerSearch, Husteblume, MASK-air and Pollen App) and one for rhinosinusitis (Galenus Health) have so far published results in the scientific literature. These apps were reviewed for their validation, discovery of novel allergy phenotypes, optimisation of identifying the pollen season, novel approaches in diagnosis and management (pharmacotherapy and allergen immunotherapy) as well as adherence to treatment. Published evidence demonstrates the potential of mobile health apps to advance in the characterisation, diagnosis and management of rhinitis and rhinosinusitis patients.